Valeant

In a new blog post, Bronte Capital analyst John Hempton explores some inconsistencies in Valeant Pharmaceuticals Intl Inc (NYSE: VRX)’s facts regarding board member Norma Provencio’s involvement in Heartronics/Signalife prior to her tenure at Valeant. After Provencio left Heartronics/...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) are now lower by 70 percent over the past three months. Analysts at Deutsche Bank and Morgan Stanley both raised concerns on the company's business. Gregg Gilbert of Deutsche Bank noted a propriety survey with doctors indicated...

Bill Ackman, hedge fund manager of Pershing Square, lashed out at Warren Buffett and Charles Munger over their large stake in The Coca-Cola Co (NYSE: KO). Ackman said Coca-Cola has "caused enormous damage to society." Last week, Munger lashed out at Valeant Pharmaceuticals Intl...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are relatively unchanged in Tuesday's after-hours session following a press release from Philidor. The specialty pharma company said it's "deeply disappointed" its working relationship with Valeant has ended, adding that it...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading higher by 2 percent early Friday morning. The stock is still lower by more than 50 percent over the past month. The New York Post reported that Bill Ackman hinted at a possible sale of the company. Shares of Valeant...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were higher by 6 percent late Monday morning. Notable short-seller Citron Research said that it will not "dial back warnings" on Valeant. Citron said that it also "stands by" its Enron analogy and that Valeant has...

Analysts at Credit Suisse recently discussed eight market moving stories. Of note, the S&P 500 index bounced higher from its overnight lows, but then sold off during the trading session. The markets were trading near flat early Monday afternoon. Analysts at Credit Suisse discussed eight...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 10 percent early Monday morning. The Wall Street Journal reported over the weekend that the relationship between Valeant and specialty pharmacies are "more intertwined than though." Valeant...

Correction: The previous version of this article, including the title, contained inaccuracies. The firm wrote it expects "an array of protracted, distracting, and expensive investigations." Those are not limited to the SEC. Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) rebounded nearly...

Pharma giant Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is crashing on Wednesday after a scathing new report from Citron Research. Shares have fallen as low as $101, a 31 percent decline. The stock opened the day's trading near $150 per share -- an enormous move for a company with a...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were lower by more than 6 percent Thursday and now down nearly 30 percent over the past three months. Valeant announced on Wednesday it has responded to government inquiries into its drug pricing practices. Sumant Kulkami of Bank of...

Shares of Pentair plc. Ordinary Share (NYSE: PNR) opened strong for trade on Tuesday after news broke that Nelson Peltz's Trian Partners has acquired a 7.24 percent stake in the company. Ed Garden, Trian Partners CIO, was on CNBC recently to discuss why the fund initiated such a large stake...